摘要
目的 分析依达拉奉右莰醇辅助治疗对急性脑梗死(acute cerebral infarction,ACI)患者氧化应激、血管内皮功能及预后的影响.方法 选取2021年9月至2022年6月北京市仁和医院收治的90例ACI患者作为研究对象,采用随机数字表法分为单治组(依达拉奉单药治疗)和联治组(依达拉奉右莰醇联合治疗),每组45例.治疗2周后,比较两组氧化应激指标、血管内皮功能指标、预后情况、疗效及不良反应发生情况.结果 治疗2周后,两组超氧化物歧化酶(superoxide dismutase,SOD)、谷胱甘肽过氧化物酶(glutathione peroxidase,GSH-Px)水平均较治疗前升高,活性氧簇(reactive oxygen species,ROS)水平较治疗前降低,且联治组SOD、GSH-Px水平高于单治组,ROS水平低于单治组,差异有统计学意义(P<0.05).治疗2周后,两组一氧化氮(nitric oxide,NO)水平较治疗前升高,血管性血友病因子(von Willebrand factor,vWF)、内皮素-1(endothelin-1,ET-1)水平均较治疗前降低,且联治组NO水平高于单治组,vWF、ET-1水平低于单治组,差异有统计学意义(P<0.05).治疗后2周后,两组改良Rankin量表(modified rankin scale,mRS)、美国国立卫生研究院卒中量表(national institute of health stroke scale,NIHSS)评分均较治疗前降低,且联治组低于单治组,差异有统计学意义(P<0.05).联治组总有效率为93.33%,高于单治组的75.56%,差异有统计学意义(P<0.05).联治组总不良反应发生率为8.89%,低于单治组的20.00%,差异无统计学意义(P>0.05).结论 依达拉奉右莰醇辅助治疗对ACI疗效明显,可减轻患者神经损伤、氧化应激反应及改善血管内皮功能效果显著,且无增加不良反应,安全性佳.
Abstract
Objective To determine the potential effect of edaravonedexborneol in the treatment of acute cerebral infarction(ACI)patient oxidative stress,vascular endothelial function,and prognosis.Methods Ninety patients with ACI admitted to Beijing Renhe Hospital from September 2021 to June 2022 were se-lected as the research group.A random number table method was used to divide these patients into the single treatment(edaravone monotherapy)and combined treatment groups(edaravonedextrol combination therapy),with 45 cases in each group.After 2 weeks of treatment,the oxidative stress indices,vascular endothelial function indices,the prognosis,the curative effect,and adverse reactions were compared between the 2 groups.Results After 2 weeks of treatment,the levels of superoxide dismutase(SOD)and glutathione peroxidase(GSH-Px)were higher than before treatment in both groups,the level of reactive oxygen species(ROS)was lower than before treatment,the levels of SOD and GSH-Px in the combined treatment group were higher than the single treatment group,and the ROS level was lower than the single treatment group;the difference was statistically significant(P<0.05).After 2 weeks of treatment,the levels of nitric oxide(NO)in the two groups were higher than before treatment,the levels of von Willebrand factor(vWF)and endothelin-1(ET-1)were both lower than those before treatment,the NO level in the combined treat-ment group was higher than the single treatment group,and the levels of vWF and ET-1 were lower than the single treatment group;the difference was statistically significant(P<0.05).After 2 weeks treatment,the modified Rankin scale(mRS)and the national institute of health stroke scale(NIHSS)scores were both lower than before treatment,and the combined treatment group were lower than the single treatment group;the differences were statistically significant(P<0.05).The total effective rate of the combined treat-ment group was 93.33%,which was higher than the single treatment group(75.56%);the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the combined treatment group was 8.89%,which was lower than the single treatment group(20.00%);the difference was not statistically significant(P>0.05).Conclusions Adjuvant therapy with edaravonedexborneol had a clear curative effect on ACI,which reduced the nerve damage,the oxidative stress response,and improved vascular endothelial function in patients without increasing adverse reactions,yet ensuring safety.
维普
万方数据